Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group

B. De Bernardi, V. Mosseri, H. Rubie, V. Castel, A. Foot, R. Ladenstein, G. Laureys, M. Beck-Popovic, A. F. De Lacerda, A. D J Pearson, J. De Kraker, P. F. Ambros, Y. De Rycke, M. Conte, P. Bruzzi, J. Michon

Research output: Contribution to journalArticlepeer-review

Abstract

Main objective of this study was to confirm that surgery alone is an effective and safe treatment for localised resectable neuroblastoma except stage 2 with amplified MYCN gene (MYCNA). Of 427 eligible stages 1-2 patients, 411 had normal MYCN and 16 had MYCNA. Of the 288 stage 1 patients with normal MYCN, 1 died of complications and 16 relapsed, 2 of whom died; 5-year relapse-free survival (RFS) and overall survival (OS) rates were 94.3% (95% confidence interval (CI): 91.6-97) and 98.9% (95% CI: 97.7-100), respectively. Of the 123 stage 2 patients with normal MYCN, 1 died of sepsis and 22 relapsed, 8 of whom died (RFS 82.8%, 95% CI: 76.2-89.5; OS 93.2%, 95% CI: 88.7-97.8). In stage 2, OS and RFS were worse for patients with elevated LDH and unfavourable histopathology. Of 16 children with MYCNA, 7 were stage 1 (5 relapses and 4 deaths) and 9 were stage 2 (3 relapses and 2 deaths) patients. In conclusion, surgery alone yielded excellent OS for both stage 1 and 2 neuroblastoma without MYCNA, although stage 2 patients with unfavourable histopathology and elevated LDH suffered a high number of relapses. Both stage 1 and 2 patients with MYCNA were at greater risk of relapse.

Original languageEnglish
Pages (from-to)1027-1033
Number of pages7
JournalBritish Journal of Cancer
Volume99
Issue number7
DOIs
Publication statusPublished - Oct 7 2008

Keywords

  • Localised
  • MYCN gene
  • Neuroblastoma
  • Prognostic factors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group'. Together they form a unique fingerprint.

Cite this